Drug lookup | Fillwise

Auro-Losartan HCT · DIN 02423642 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Losartan HCT · DIN 02423642 Manufacturer: Auro Pharma Inc.; listing date 2014-07-30 Health Canada: Marketed since 2014-04-29 · brand AURO-LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, LOSARTAN POTASSIUM 50 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Losartan HCT: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90835 · Verify on the e-Formulary ↗ (DIN 02423642)

Source record

DIN 02423642: Auro-Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id AUR Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423642 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90835

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2025-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423642

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hyzaar · DIN 02230047 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Hyzaar · DIN 02230047 Manufacturer: Organon Canada Inc.; listing date 2000-11-30 Health Canada: Marketed since 2022-03-03 · brand HYZAAR · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48580 · Verify on the e-Formulary ↗ (DIN 02230047)

Source record

DIN 02230047: Hyzaar Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id OCI Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.9924; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230047 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48580

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2023-09-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230047

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan HCT · DIN 02388960 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan HCT · DIN 02388960 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-09-30 Health Canada: Marketed since 2025-10-07 · brand LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan HCT: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87449 · Verify on the e-Formulary ↗ (DIN 02388960)

Source record

DIN 02388960: Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id SIV Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388960 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87449

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: active shortage (reported 2021-10-13, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388960

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan/HCTZ · DIN 02427648 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan/HCTZ · DIN 02427648 Manufacturer: Sanis Health Inc.; listing date 2021-01-29 Health Canada: Marketed since 2014-07-25 · brand LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan/HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91215 · Verify on the e-Formulary ↗ (DIN 02427648)

Source record

DIN 02427648: Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id SAI Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427648 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91215

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2025-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427648

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Losartan/HCTZ · DIN 02389657 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Losartan/HCTZ · DIN 02389657 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-09-28 Health Canada: Marketed since 2024-06-14 · brand MINT-LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, LOSARTAN POTASSIUM 50 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Losartan/HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87515 · Verify on the e-Formulary ↗ (DIN 02389657)

Source record

DIN 02389657: Mint-Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id MIN Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389657 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87515

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2024-06-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389657

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Losartan-HCTZ · DIN 02392224 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Losartan-HCTZ · DIN 02392224 Manufacturer: Pharmascience Inc.; listing date 2012-10-30 Health Canada: Marketed since 2012-09-04 · brand PMS-LOSARTAN-HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Losartan-HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87750 · Verify on the e-Formulary ↗ (DIN 02392224)

Source record

DIN 02392224: PMS-Losartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392224 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87750

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2026-05-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392224

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Losartan HCT · DIN 02313375 · 50mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Losartan HCT · DIN 02313375 Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2012-01-25 · brand SANDOZ LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Losartan HCT: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79890 · Verify on the e-Formulary ↗ (DIN 02313375)

Source record

DIN 02313375: Sandoz Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id SDZ Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313375 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79890

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: resolved shortage (ended 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313375

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Losartan HCT · DIN 02423650 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Losartan HCT · DIN 02423650 Manufacturer: Auro Pharma Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-04-29 · brand AURO-LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Losartan HCT: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90836 · Verify on the e-Formulary ↗ (DIN 02423650)

Source record

DIN 02423650: Auro-Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423650 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90836

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: resolved shortage (ended 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423650

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Losartan HCT · DIN 02423669 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Losartan HCT · DIN 02423669 Manufacturer: Auro Pharma Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-04-29 · brand AURO-LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, LOSARTAN POTASSIUM 100 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Losartan HCT: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90837 · Verify on the e-Formulary ↗ (DIN 02423669)

Source record

DIN 02423669: Auro-Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423669 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90837

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423669

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hyzaar · DIN 02297841 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Hyzaar · DIN 02297841 Manufacturer: Organon Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2022-04-05 · brand HYZAAR · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78318 · Verify on the e-Formulary ↗ (DIN 02297841)

Source record

DIN 02297841: Hyzaar Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id OCI Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.9508; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297841 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78318

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: resolved shortage (ended 2023-09-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297841

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hyzaar DS · DIN 02241007 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Hyzaar DS · DIN 02241007 Manufacturer: Organon Canada Inc.; listing date 2000-11-30 Health Canada: Marketed since 2022-04-01 · brand HYZAAR DS · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 25 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64599 · Verify on the e-Formulary ↗ (DIN 02241007)

Source record

DIN 02241007: Hyzaar DS Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id OCI Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.9924; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241007 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64599

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: shortage reported ended 2026-08-21 (report last updated 2026-08-21); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241007

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan HCT · DIN 02388979 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan HCT · DIN 02388979 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-09-30 Health Canada: Marketed since 2025-10-07 · brand LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, LOSARTAN POTASSIUM 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan HCT: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87450 · Verify on the e-Formulary ↗ (DIN 02388979)

Source record

DIN 02388979: Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388979 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87450

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: active shortage (reported 2021-10-13, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388979

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan HCT DS · DIN 02388987 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan HCT DS · DIN 02388987 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-09-30 Health Canada: Marketed since 2025-10-07 · brand LOSARTAN HCT DS · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, LOSARTAN POTASSIUM 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan HCT DS: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87451 · Verify on the e-Formulary ↗ (DIN 02388987)

Source record

DIN 02388987: Losartan HCT DS Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388987 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87451

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2025-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388987

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan/HCTZ · DIN 02427656 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan/HCTZ · DIN 02427656 Manufacturer: Sanis Health Inc.; listing date 2021-01-29 Health Canada: Marketed since 2020-08-25 · brand LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan/HCTZ: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91216 · Verify on the e-Formulary ↗ (DIN 02427656)

Source record

DIN 02427656: Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427656 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91216

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: resolved shortage (ended 2024-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427656

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Losartan/HCTZ · DIN 02427664 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Losartan/HCTZ · DIN 02427664 Manufacturer: Sanis Health Inc.; listing date 2021-01-29 Health Canada: Marketed since 2014-07-25 · brand LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 25 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Losartan/HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91217 · Verify on the e-Formulary ↗ (DIN 02427664)

Source record

DIN 02427664: Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427664 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91217

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2025-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427664

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Losartan/HCTZ · DIN 02389665 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Losartan/HCTZ · DIN 02389665 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-09-28 Health Canada: Marketed since 2024-06-14 · brand MINT-LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, LOSARTAN POTASSIUM 100 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Losartan/HCTZ: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87516 · Verify on the e-Formulary ↗ (DIN 02389665)

Source record

DIN 02389665: Mint-Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389665 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87516

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: resolved shortage (ended 2023-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389665

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Losartan/HCTZ DS · DIN 02389673 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Losartan/HCTZ DS · DIN 02389673 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-09-28 Health Canada: Marketed since 2024-06-14 · brand MINT-LOSARTAN/HCTZ DS · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25.0 MG, LOSARTAN POTASSIUM 100.0 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Losartan/HCTZ DS: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87517 · Verify on the e-Formulary ↗ (DIN 02389673)

Source record

DIN 02389673: Mint-Losartan/HCTZ DS Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389673 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87517

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2024-06-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389673

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Losartan-HCTZ · DIN 02392232 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Losartan-HCTZ · DIN 02392232 Manufacturer: Pharmascience Inc.; listing date 2012-10-30 Health Canada: Marketed since 2012-09-04 · brand PMS-LOSARTAN-HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, LOSARTAN POTASSIUM 100 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Losartan-HCTZ: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87751 · Verify on the e-Formulary ↗ (DIN 02392232)

Source record

DIN 02392232: PMS-Losartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392232 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87751

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 Sandoz Losartan HCT · DIN 02362449 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: resolved shortage (ended 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392232

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Losartan-HCTZ · DIN 02392240 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Losartan-HCTZ · DIN 02392240 Manufacturer: Pharmascience Inc.; listing date 2012-10-30 Health Canada: Marketed since 2012-09-04 · brand PMS-LOSARTAN-HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, LOSARTAN POTASSIUM 100 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Losartan-HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87752 · Verify on the e-Formulary ↗ (DIN 02392240)

Source record

DIN 02392240: PMS-Losartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87752

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2022-01-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392240

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Losartan HCT · DIN 02362449 · 100mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Losartan HCT · DIN 02362449 Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2012-01-25 · brand SANDOZ LOSARTAN HCT · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Losartan HCT: Formulary list price $0.3082/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3082 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84745 · Verify on the e-Formulary ↗ (DIN 02362449)

Source record

DIN 02362449: Sandoz Losartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800282; group id 336; item number 0760; lccId None; manufacturer id SDZ Source form: Tab; strength: 100mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3082; ministry $0.3082 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362449 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84745

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371243 · $0.3082 Auro-Losartan HCT · DIN 02423650 · $0.3082 Co Losartan/HCT · DIN 02388278 · $0.3082 Hyzaar · DIN 02297841 · $0.3082 Losartan HCT · DIN 02388979 · $0.3082 Losartan/HCTZ · DIN 02427656 · $0.3082 Mint-Losartan/HCTZ · DIN 02389665 · $0.3082 PMS-Losartan-HCTZ · DIN 02392232 · $0.3082 Teva-Losartan/HCTZ · DIN 02377144 · $0.3082

Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02362449

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Losartan HCT DS · DIN 02313383 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Losartan HCT DS · DIN 02313383 Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2012-01-25 · brand SANDOZ LOSARTAN HCT DS · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, LOSARTAN POTASSIUM 100 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Losartan HCT DS: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79891 · Verify on the e-Formulary ↗ (DIN 02313383)

Source record

DIN 02313383: Sandoz Losartan HCT DS Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id SDZ Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313383 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79891

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Septa-Losartan HCTZ · DIN 02428547 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313383

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Septa-Losartan HCTZ · DIN 02428539 · 50mg & 12.5mg · tablet

General benefitDormant since 2017-07-21 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Septa-Losartan HCTZ · DIN 02428539 Manufacturer: Septa Pharmaceuticals Inc.; listing date 2014-12-18 Health Canada: Dormant since 2017-07-21 · brand SEPTA-LOSARTAN HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Septa pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Septa-Losartan HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91300 · Verify on the e-Formulary ↗ (DIN 02428539)

Source record

DIN 02428539: Septa-Losartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id SET Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428539 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91300

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371235 · $0.3147 Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428539

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2017-07-21 — choose a marketed DIN from the same-category list.

Septa-Losartan HCTZ · DIN 02428547 · 100mg & 25mg · tablet

General benefitDormant since 2017-07-21 · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Septa-Losartan HCTZ · DIN 02428547 Manufacturer: Septa Pharmaceuticals Inc.; listing date 2014-12-18 Health Canada: Dormant since 2017-07-21 · brand SEPTA-LOSARTAN HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG, HYDROCHLOROTHIAZIDE 25 MG · company Septa pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Septa-Losartan HCTZ: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91301 · Verify on the e-Formulary ↗ (DIN 02428547)

Source record

DIN 02428547: Septa-Losartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800241; group id 336; item number 0762; lccId None; manufacturer id SET Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3147; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428547 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91301

Interchangeable products

Apo-Losartan/HCTZ · DIN 02371251 · $0.3147 Auro-Losartan HCT · DIN 02423669 · $0.3147 Co Losartan/HCT · DIN 02388286 · $0.3147 Hyzaar DS · DIN 02241007 · $0.3147 Jamp-Losartan HCTZ · DIN 02408252 · $0.3147 Losartan HCT DS · DIN 02388987 · $0.3147 Losartan/HCTZ · DIN 02427664 · $0.3147 Mint-Losartan/HCTZ DS · DIN 02389673 · $0.3147 PMS-Losartan-HCTZ · DIN 02392240 · $0.3147 Sandoz Losartan HCT DS · DIN 02313383 · $0.3147 Teva-Losartan/HCTZ · DIN 02377152 · $0.3147

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428547

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2017-07-21 — choose a marketed DIN from the same-category list.

Apo-Losartan/HCTZ · DIN 02371235 · 50mg & 12.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Losartan/HCTZ · DIN 02371235 Manufacturer: Apotex Inc.; listing date 2012-03-26 Health Canada: Cancelled post market since 2025-04-17 · brand APO-LOSARTAN/HCTZ · ATC C09DA01 LOSARTAN AND DIURETICS, C09DA01 LOSARTAN AND DIURETICS · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85641 · Verify on the e-Formulary ↗ (DIN 02371235)

Source record

DIN 02371235: Apo-Losartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800226; group id 336; item number 0761; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3148; ministry $0.3147 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85641

Interchangeable products

Auro-Losartan HCT · DIN 02423642 · $0.3147 Co Losartan/HCT · DIN 02388251 · $0.3147 Hyzaar · DIN 02230047 · $0.3147 Jamp-Losartan HCTZ · DIN 02408244 · $0.3147 Losartan HCT · DIN 02388960 · $0.3147 Losartan/HCTZ · DIN 02427648 · $0.3147 Mint-Losartan/HCTZ · DIN 02389657 · $0.3147 PMS-Losartan-HCTZ · DIN 02392224 · $0.3147 Sandoz Losartan HCT · DIN 02313375 · $0.3147 Septa-Losartan HCTZ · DIN 02428539 · $0.3147 Teva-Losartan/HCTZ · DIN 02358263 · $0.3147

Shortage status: discontinued (2018-11-19, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371235

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Look up one drug

LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE

Auro-Losartan HCT · DIN 02423642 · 50mg & 12.5mg · tablet

Hyzaar · DIN 02230047 · 50mg & 12.5mg · tablet

Losartan HCT · DIN 02388960 · 50mg & 12.5mg · tablet

Losartan/HCTZ · DIN 02427648 · 50mg & 12.5mg · tablet

Mint-Losartan/HCTZ · DIN 02389657 · 50mg & 12.5mg · tablet

PMS-Losartan-HCTZ · DIN 02392224 · 50mg & 12.5mg · tablet

Sandoz Losartan HCT · DIN 02313375 · 50mg & 12.5mg · tablet

Auro-Losartan HCT · DIN 02423650 · 100mg & 12.5mg · tablet

Auro-Losartan HCT · DIN 02423669 · 100mg & 25mg · tablet

Hyzaar · DIN 02297841 · 100mg & 12.5mg · tablet

Hyzaar DS · DIN 02241007 · 100mg & 25mg · tablet

Losartan HCT · DIN 02388979 · 100mg & 12.5mg · tablet

Losartan HCT DS · DIN 02388987 · 100mg & 25mg · tablet

Losartan/HCTZ · DIN 02427656 · 100mg & 12.5mg · tablet

Losartan/HCTZ · DIN 02427664 · 100mg & 25mg · tablet

Mint-Losartan/HCTZ · DIN 02389665 · 100mg & 12.5mg · tablet

Mint-Losartan/HCTZ DS · DIN 02389673 · 100mg & 25mg · tablet

PMS-Losartan-HCTZ · DIN 02392232 · 100mg & 12.5mg · tablet

PMS-Losartan-HCTZ · DIN 02392240 · 100mg & 25mg · tablet

Sandoz Losartan HCT · DIN 02362449 · 100mg & 12.5mg · tablet

Sandoz Losartan HCT DS · DIN 02313383 · 100mg & 25mg · tablet

Septa-Losartan HCTZ · DIN 02428539 · 50mg & 12.5mg · tablet

Septa-Losartan HCTZ · DIN 02428547 · 100mg & 25mg · tablet

Apo-Losartan/HCTZ · DIN 02371235 · 50mg & 12.5mg · tablet

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

IRBESARTAN & HYDROCHLOROTHIAZIDE

OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE

TELMISARTAN & HYDROCHLOROTHIAZIDE

VALSARTAN & HYDROCHLOROTHIAZIDE

EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE

TELMISARTAN & AMLODIPINE BESYLATE

ATENOLOL & CHLORTHALIDONE

BENAZEPRIL

CANDESARTAN CILEXETIL

CAPTOPRIL

CILAZAPRIL

Availability